The application of fluorescein sodium for the resection of medulloblastoma

Zheng-he Chen1,2,3 · Xiang-heng Zhang1,2 · Fu-hua Lin1,2,3 · Chang Li1,2,3 · Jie-tian Jin2,3,4 · Zhi-huan Zhou1,2,3 · Si-han Zhu1,2,3 · Zhu-qing Cheng1,2,3 · Sheng Zhong1,2,3 · Zhen-qiang He1,2,3 · Hao Duan1,2,3 · Xia Wen1,2,3 · Jian Wang1,2,3 · Yong-gao Mou1,2,3

Received: 30 July 2021 / Accepted: 11 May 2022 / Published online: 3 June 2022
© The Author(s) 2022

Abstract

Introduction Surgical resection of medulloblastoma (MB) remains a challenge. At present, a variety of tracers have been used for intraoperative tumor visualization. However, there are few reports on the intraoperative visualization of MB. Hence, we reported our experience of applying fluorescein sodium (FS) in MB surgery.

Methods We retrospectively analyzed the clinical information of patients with MB confirmed by surgery and pathology from January 2016 to December 2020 from Sun Yat-sen University Cancer Center. A total of 62 patients were enrolled, of which 27 received intraoperative FS and 35 did not. The intraoperative dose of FS was 3 mg/kg.

Results Among the 62 patients, 42 were males, and twenty were females. The age of onset in the FS group was 9.588 ± 7.322, which in the non-fluorescein sodium group was 13.469 ± 10.968, p = 0.198. We did not find significant differences in tumor location, tumor size, tumor resection, tumor histology, and preoperative symptoms (hydrocephalus, headache, vomit, balance disorder) between the groups. There was no significant difference in the postoperative symptoms (hydrocephalus, headache, vomiting, balance disorder, and cerebellar mutism). However, patients in the FS group had a relatively low incidence of balance disorder and cerebellar mutism. There was definite fluorescence of tumor in all cases of the FS group, and even the tiny metastatic lesion was visible. No case had side effects related to the use of FS.

Conclusions FS is safe and effective in MB surgery. Whether the application of FS for surgery can reduce complications remains to be studied in the future.

Keywords Fluroescein sodium · Medulloblastoma · Tumor visualization · Resection

Introduction

Medulloblastoma (MB) is the most common malignancy in childhood brain tumors. The current management strategies for this disease are maximal surgical resection followed by craniospinal irradiation and adjuvant chemotherapy. Despite this multipronged approach to therapy, nearly one-third of MB patients die from this disease [1]. Patients of MB have an increased risk of poor quality of life due to the severe adverse effects of MB and its management. Although researchers found that gene mutations dominate the final fate of this disease, surgery still plays a critical role in the management of MB. The extent of surgical resection remains a prognostic factor. Patients > 3 years of age who underwent a gross total resection (GTR) or near total resection (NTR; < 1.5cm² residual tumor) have better outcomes compared with those who underwent subtotal resection (STR) [2, 3]. But trying to reach GTR or NTR goal may cause disastrous complications, such as impaired speech, cognition, and motor function. Intra-operative neurophysiological monitoring reminds surgeons of the existence of neural tracts in the brain stem, however, differentiating the precise border of the tumor is still a challenge.

Tumor visualization is a potential technology to benefit the resection of tumors. Several agents have demonstrated their value in various kinds of malignancy. 5-aminolevulinic acid (5-ALA), a natural biochemical precursor of
hemoglobin that improves the synthesis and concentration of fluorescent porphyrins in various tumors, is used in EURO and USA [4, 5]. However, due to the high cost of 5-ALA, Fluorescein sodium (FS) is an alternative fluorophore, which is inexpensive and biosafe. Studies reveal FS can strongly stain the contrast enhancement regions in high grade gliomas (HGGs) [6–8], and benefit the sampling of low grade glioma [9]. But there is only one case report depicting the application of FS in the surgical resection of MB [10].

Hence, we retrospectively analyzed our experiences with the application of FS in 27 MB patients and proposed that fluorescein is safe and effective in the resection of MB.

Methods

Patients

Clinical, pre-, and post-operative gadolinium-enhanced magnetic resonance imaging (MRI), surgical and histopathological data of a total of 62 patients with the diagnosis of MB from January 2016 to December 2020 from Sun Yat-sen University Cancer Center were collected. The patients were dichotomized whether the FS was used or not. Among them, 27 patients underwent FS-guided operations. All patients had symptoms caused by neurologic deterioration. The patients were followed up by clinical examination and MRI every 3 to 6 months after surgery. The extent of tumor resection was evaluated by comparing the results of pre-operative and post-operative neuroimaging. The tumor size was evaluated by the Chang Staging Classification [11]. Written informed consent was obtained on behalf of the adult patients or child patients from parents.

Protocol for fluorescein sodium guided surgery

54 patients underwent a standard suboccipital craniotomy, achieving the goal of gross total resection for MB in the posterior fossa. Seven patients underwent a retrosigmoid approach, and 1 patient performed a supratentorial approach. The standard FS guided operation was previously reported [12]. At induction, a predefined dose of 3 mg/kg of FS was injected intravenously via a central line prior to general anesthesia, after the negative FLS skin test was obtained. With planting the electrodes of intraoperative neuro-monitoring, the patient was laid in the prone position, and the head was fixed in a Mayfield head-holder. No need for the maximum flexibility of the neck in case of focal intracranial hypertension. Operations were performed under white light using an operation microscope (neurosurgery microscope OPMI PENTERO 900, German Carl Zeiss Meditec AG) and the neurosurgeon repeatedly switched into blue illumination mode to visualize yellow fluorescence in the operative field. Neurophysiological monitoring techniques, such as Somatosensory Evoked Potentials (SSEP), Motor Evoked Potentials (MEP), and Brainstem Auditory Evoked Potentials (BAEP), were applied.

After identifying the marginal zone of tumor invasion under the yellow fluorescence field, the operation proceeded while the microscope was switched into the white light mode. With surgery proceeding, the surgeon could switch to a different light mode to meet the demand of surgical requirements.

Statistical analyses

Nominal variables were analyzed using a two-tailed Fisher's exact test or chi-square test followed by post hoc two-tailed Fisher's exact tests when applicable. Ordinal and continuous variables were analyzed with the Mann–Whitney U test. P-values with corresponding odds ratios (OR) were presented in the tables. P < 0.05 was considered statistically significant. Tests were performed using R software version 3.6.2 and SPSS software (v24.0).

Univarient and multivariant analyses

To assess the factors that are related to the OS of the patients, univarient and multivariant analyses were performed between the FS and non-FS subgroups by integrating clinical variables including the age, gender, tumor histology, tumor location, type of resection, presence of pre-op hydrocephalus, headache, vomit, etc. Variables that were observed with significant differences between FS and non-FS subgroups in the univariate analysis were selected for multivariate analysis.

Survival analysis

The p-value for survival analysis was calculated using R packages “survival” and “surveminer” based on the overall survival (OS) of the patients [13]. Kaplan–Meier survival (K–M) curves were plotted for FS and non-FS subgroups. Patients without information were excluded.

Results

Descriptive parameters

Sixty-two consecutive patients, 42 males, and twenty females were diagnosed with MB. The patients' ages ranged from 1 year and 19 months to 48 years. The FS-guided operation proceeded in 27(43.5%) patients. Both the FS group and NFS group were comparable in terms of gender, age at surgery, pre-op hydrocephalus, headache, vomit, balance
disorder, tumor location, tumor size, histology, and resection (Table 1). No significance was found.

To identify whether the use of FS was a benefit to the alleviation of symptoms, we analyzed the appearance of post-op symptoms in the FS group and NFS group. Whether it was about “hydrocephalus”, “headache”, “vomit”, “balance disorder” or “cerebellar mutism”, we did not find significant statistical differences (Table 2). Regarding the two types of symptoms of “balance disorder” and “cerebellar mutism, the incidence in the FS group was lower than that of NFS. They are 7.4% vs. 20%, and 3.7% vs. 20%, respectively.

Univariate analysis of the clinical variables was performed (Table 3), and no statistically significant differences were observed, thus no variable was selected for multivariate analysis.

**Fluorescence of MB**

In FS guided group, after a one-hour course of craniotomy, all tumors had a homogeneous and moderate yellow fluorescence under the yellow 560 nm filter (Fig. 1). When the tumor was removed, the compression of the Sylvius aqueduct was relieved, with yellow-tinged cerebral spinal fluid issued (Figs. 1 c, d). The fluorescence was very sensitive and even appeared in the tiny metastatic lesion less than 2 mm in diameter (Fig. 2).

The stable fluorescence of the tumor lasted nearly three hours on average. We did not observe any adverse effects, anaphylactic reactions, or postoperative neurological deterioration related to the fluorescein sodium-guided surgery.

**Survival analysis for both groups**

Survival analysis for both groups has been made (Fig. 3). No significant difference between the OS of FS and NFS was observed.

**Discussion**

Our retrospective study is the first report of a large sample of cases revealing the evaluation of fluorescein sodium guidance adjunct in the resection of medulloblastoma. We suggested that fluorescence can visualize the extent of the tumor, even the marginal metastatic lesion. No adverse side effects were found.

MB is the most common malignant brain tumor in children, and it can also affect a portion of the adult. It is an embryonal tumor of the cerebellum, derived from the discrete neuronal stem or progenitor cell. Formerly, MB has been classified into three major forms based on histology: classic, nodular/desmoplasic (ND), and large cell/anaplastic (LCA) [14]. In 2016, with the advances in genomics,
the WHO consensus on the MB subgroup divided it into 4 major subgroups: WNT, SHH, Group 3, and Group 4 [15]. Despite progress in the diagnosis and therapies, one-third of MB causes the death of the patient [1]. The survivors usually suffer grievous clinical complications, such as cognitive deficits, cerebellar mutism, and secondary malignancy [16–18].

Surgery plays an important role in the standard management strategies for MB, achieving the sample for diagnosis, alleviating the mass effect, and rebuilding the CSF pathway. Albright et al. retrospectively reviewed 188 patients who underwent craniotomy for resection of MB, they concluded that the extent of residual tumor did correlate with good prognosis in certain children [2]. Thompson et al. made a retrospective multi-center integrated clinical and molecular analysis on the prognostic value of the extent of resection, in which 787 patients were enrolled. They reported a PFS benefit for GTR over STR (hazard ratio [HR] 1.45, 95% CI 1.07–1.96, p = 0.16) but no OS benefit (HR 1.23, 0.87–1.72, p = 0.24). No PFS or OS benefit for GTR or NTR was found [3]. Radical resection of the primary tumor is strongly encouraged at diagnosis, but not at the expense of causing permanent brain injury. GTR or NTR may cause disastrous complications. Intra-operative neurophysiological monitoring reminds surgeons of the existence of neural tract in the brain stem, however, differentiating the precise border of the tumor is still a challenge.

Tumor visualization is currently a method of surgical treatment. At present, the commonly used tumor imaging agents are 5-ALA, FS, and indocyanine green. Among them, there are still few reports on the application of tumor imaging agents for surgical removal of MB. Regarding 5-ALA, only 4 studies have been published so far. Two studies reported the application of 5-ALA in MB cell lines [19, 20]. Stummer et al. et al. surveyed 5-ALA for the treatment of pediatric brain tumors, 5-ALA fluorescence was useful in 2 of 8 cases of MB (25%) [21]. Eicker et al. reported the application of 5-ALA in spinal cord tumor surgery, in which one patient had spinal cord metastasis of MB [22]. Roth et al. reported their experience in the use of 5-ALA in pediatric brain tumors. They found that aside from the GBM, 5-ALA showed a limited fluorescence amongst pediatric brain tumors, including MB [23]. One possible reason may be that differences in the mitochondrial enzyme ferrochelatase, which is thought to be downregulated in GBM cells, thus upgraded the level of protoporphyrin IX emits the fluorescence [24].

Although 5-ALA has been approved for use in countries such as Europe, Asia, and the United States. However, no approval for clinical use of 5-ALA has been obtained in China.

FS is a dye that can accumulate in the area of blood brain barrier (BBB) breakdown, presenting a major excitation wavelength peak ranging from 460 to 500 nm, and a major green emission peak fluorescent radiation ranging from 540 to 690 nm [6]. The intact BBB prevents the uptake of FS, however, the existence of a tumor can impair the BBB. It provides a good visualization of the tumor. FS can be applied to aid in the identification of several brain tumor types in 1948 [25]. Since then, literature reports on the application of FS in tumors have gradually increased. FS has been reported to provide significant advantages in the extent of resection for HGGs [26–28], including

### Table 2

| Variable       | FS n (%) | NFS n (%) | P-value | OR  |
|----------------|----------|-----------|---------|-----|
| Hydrocephalus  | 1(7.4)   | 2(5.7)    | 1.320   |     |
| Headache       | 0(0)     | 0(0)      |         |     |
| Vomit          | 0(0)     | 1(2.9)    | 1.794   |     |
| Balance disorder| 2(7.4)  | 7(20)     | 0.277   | 0.320|
| Cerebellar mutism | 1(3.7) | 7(20)     | 0.123   | 0.154|

**FS** fluorescein sodium, **MB** medulloblastoma, **NA** not available, **NFS** non-fluorescein sodium, **OR** odds ratio

### Table 3

| Variable                        | OR     | 95% CI   | p-value |
|---------------------------------|--------|----------|---------|
| Gender (male/female)            | 1.986  | 0.675–5.842 | 0.213   |
| Histology (classic/Des/LCA/NOS) | 0.834  | 0.587–1.186 | 0.313   |
| Location (vermis/hemisphere/bilateral) | 1.704 | 0.538–5.4 | 0.365   |
| Resection (GTR/NTR/STR/Biopsy) | 1.017  | 0.555–1.864 | 0.956   |
| Age at surgery                  | 2.320  | 0.714–7.537 | 0.162   |
| Pre-op hydrocephalus            | 2.232  | 0.397–12.543 | 0.362   |
| Headache                        | 0.765  | 0.246–2.378 | 0.643   |
| Vomit                           | 1.295  | 0.438–3.834 | 0.640   |
| Balance disorder                | 0.668  | 0.257–1.741 | 0.409   |
| Tumor size (1/2/3/4)            | 0.844  | 0.429–1.664 | 0.625   |
| KPS (< 70/ ≥ 70)                | 0.000  | 0–0       | 1.000   |
| Recurrence                      | 1.216  | 0.396–3.732 | 0.732   |
recurrent glioblastomas [29]. It is usually effective for the malignances which were significantly enhanced in preoperative MRI scans, such as metastatic tumors, and lymphoma [12, 30, 31]. Studies reported that FS is a feasible technique for deep-seated malignant brain tumors [12, 32]. Similar results have been reported in the spinal cord [33]. FS is also of equal value in the surgical treatment of benign tumors [34], and facilitates guided sampling in non-enhancing gliomas [9].

However, since the role of the FS depends on the destruction of the BBB, this also affects its reliability. We found that, as the operation progressed, normal brain

---

**Fig. 1** An 8-year-old boy underwent fluorescein sodium guided surgery for medulloblastoma of the cerebellar vermis. a The tumor (showed the white dashed frame) herniated from the cerebellomedullary fissure under the white light and (b) the yellow light. When the tumor was removed, the opening of the midbrain aqueduct (e, the white light mode; d, the yellow light mode) (blue arrow) and the fourth ventricle were revealed (e, the white light mode; f, the yellow light mode). g, h Sagittal magnetic resonance imaging shows complete removal of the tumor.

**Fig. 2** Illustration of the value of fluorescein sodium in the visualization of micrometastasis. A 7-year-old boy underwent surgery for medulloblastoma of the cerebellar vermis with the aid of fluorescein sodium. The tumor tissue was shown in the area of the white dashed (a, the white light mode; b, the yellow light mode). A tiny metastatic lesion (blue arrow) was found in the left cerebellar hemisphere under the yellow light mode and diagnosed as medulloblastoma with a feature of a dominant population of undifferentiated cells with a high nuclear-to-cytoplasmic ratio and mitotic (e).
tissue shrinkage and hemorrhage could cause obvious background interference to fluorescence imaging, making it difficult to confirm tumor boundaries solely by fluorescence.

But to the best of my knowledge, the use of FS in the surgery of MB has been reported only in one case [10]. Alysa Almojuela et al. reported the first application of FS in a 5-year-old female diagnosed as MB. But there are no more studies published about FS utilized to aid in the resection of MB. Our research shows evidence of the safety and efficiency of FS in the resection of MB. The FS-guided group can find stable fluorescence in the operation, even if the tiny satellite lesion is localized. We considered the use of FS as a promising surgical tool.

Since we started FS surgery in 2018, the number of surgical cases is still limited. And the limitation of pathologic classification in our hospital weakened the research. In terms of the benefit of FS in the protection of CNS function, our result did not provide a positive outcome. That may be due to the sample size of this research. The incidence of several symptoms was reduced in the FS group, although there was no significant difference compared with the NFS group. But we believe that there may be different results later when the sample size can be expanded.

Conclusions

Fluorescein sodium is a safe and effective adjunct in the resection of medulloblastoma. The fluorescence in the operation is stable. Fluorescein sodium has a good potential application value in surgery, and further research is needed in the future.

Author contributions ZHC, XHZ, FHL, and CL contributed equally to this work. ZHC, XHZ, and FHL drafted the manuscript. CL performed the statistical calculation. JTJ, ZHZ, SHZ, ZQC, SZ, ZQH, HD, XW performed data collection. JW and YGM supervised the data collection and revised this article. All authors read and approved the final manuscript.

Funding This work was supported by the Science and Technology Program of Guangzhou, China (Grant number 201704020133); National Natural Science Foundation of China (Grant number 52075285). The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Data availability The data during and/or analyzed during the current study are available from the corresponding author.

Code availability Not applicable.

Declarations

Conflict of interest The authors have no relevant financial or non-financial interest to disclose.

Ethical approval Study approval was obtained from the Medical Ethics Committees of SYSUCC and the study was conducted following the ethical standard of the World Medical Association Declaration of Helsinki.

Informed consent Informed consent was obtained from all individual participants included in the study. All patients were provided written informed consent for their information to be stored and published in the hospital database.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Polkinghorn WR, Tarbell NJ (2007) Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4(5):295–304
2. Albright AL et al (1996) Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 38(2):265–271
3. Thompson EM et al (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17(4):484–495
4. Widhalm G et al (2013) 5-Aminolevulinic acid induced fluorescence is a powerful intraoperative marker for precise histopathological grading of gliomas with non-significant contrast-enhancement. PLoS One 8(10):e76988
5. Widhalm G et al (2010) 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 116(6):1545–1552
6. Diaz RJ et al (2015) Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance. J Neurosurg 122(6):1360–1369
7. Chen B et al (2012) Gross total resection of glioma with the intraoperative fluorescence-guidance of fluorescein sodium. Int J Med Sci 9(8):708–714
8. Acerbi F et al (2014) Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurg Focus 36(2):E5
9. Bowden SG et al (2018) Sodium fluorescein facilitates guided sampling of diagnostic tumor tissue in nonenhancing gliomas. Neurosurgery 82(5):719–727
10. Almojuela A et al (2020) Using fluorescein in the resection of a pediatric posterior fossa tumor. Can J Neurol Sci 47(4):578–580
11. Chang CH, Housepian EM, Herbert C Jr (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93(6):1351–1359
12. Lin FH et al (2018) Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI. J Neurooncol 139(3):757–765
13. Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York, NY
14. Ellison DW (2010) Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol 120(3):305–316
15. Louis DN et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820
16. Veneroni L et al (2017) Quality of life in long-term survivors treated for metastatic medulloblastoma with a hyperfractionated accelerated radiotherapy (HART) strategy. Childs Nerv Syst 33(11):1969–1976
17. King AA et al (2017) Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/ PNET: a report from the childhood cancer survivor study. Neuro Oncol 19(5):689–698
18. Phi JH et al (2018) Genomic analysis reveals secondary glioblastoma after radiotherapy in a subset of recurrent medulloblastomas. Acta Neuropathol 135(6):939–953
19. Briel-Pump A et al (2018) Accumulation of protoporphyrin IX in medulloblastoma cell lines and sensitivity to subsequent photodynamic treatment. J Photochem Photobiol B 189:298–305
20. Ritz R et al (2012) In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells. PLoS One 7(12):e51974
21. Stummer W et al (2014) Predicting the “usefulness” of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European survey. Acta Neurochir 156(12):2315–2324
22. Eicker SO et al (2013) The impact of fluorescence guidance on spinal intradural tumour surgery. Eur Spine J 22(6):1394–1401
23. Roth J, Constantini S (2017) 5ALA in pediatric brain tumors is not routinely beneficial. Childs Nerv Syst 33(5):787–792
24. Inoue K et al (2009) Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas. Pathobiology 76(6):303–314
25. Moore GE, Peyton WT et al (1948) The clinical use of fluorescein in neurosurgery; the localization of brain tumors. J Neurosurg 5(4):392–398
26. Shinoda J et al (2003) Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Tech note J Neurosurg 99(3):597–603
27. Koc K et al (2008) Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 22(1):99–103
28. Katsevman GA et al (2019) Utility of sodium fluorescein for achieving resection targets in glioblastoma: increased gross— or near-total resections and prolonged survival. J Neurosurg 132(3):914–920
29. Höhere J et al (2019) Fluorescein sodium in the surgical treatment of recurrent glioblastoma multiforme. World Neurosurg 125:e158–e164
30. Okuda T et al (2010) Fluorescence-guided surgery of metastatic brain tumors using fluorescein sodium. J Clin Neurosci 17(1):118–121
31. Schebesch KM et al (2015) Fluorescein sodium-guided surgery in cerebral lymphoma. Clin Neurol Neurosurg 139:125–128
32. Kutlay M et al (2021) Fluorescein sodium-guided neuroendoscopic resection of deep-seated malignant brain tumors: preliminary results of 18 patients. Oper Neurosurg 20(2):206–218
33. Olguin SK et al (2020) Sodium fluorescein for spinal intradural tumors. Front Oncol 10:618579
34. Minkin K et al (2016) Intraoperative fluorescein staining for papillary carcinoma of the thyroid gland. Acta Neuropathol 136(1):2315–2324

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Zheng-he Chen¹,²,³ · Xiang-heng Zhang¹,²,³ · Fu-hua Lin¹,²,³ · Chang Li¹,²,³ · Jie-tian Jin²,³,⁴ · Zhi-huan Zhou¹,²,³ · Si-han Zhu¹,²,³ · Zhu-qing Cheng¹,²,³ · Sheng Zhong¹,²,³ · Zhen-qiang He¹,²,³ · Hao Duan¹,²,³ · Xia Wen¹,²,³ · Jian Wang¹,²,³ · Yong-gao Mou¹,²,³

Zheng-he Chen
chenzhengh@sysucc.org.cn
Xiang-heng Zhang
zhangxh@sysucc.org.cn
Fu-hua Lin
linfuh@sysucc.org.cn
Chang Li
lichang1@sysucc.org.cn
Jie-tian Jin
jinjt@sysucc.org.cn
Zhi-huan Zhou
zhouzhh@sysucc.org.cn
Si-han Zhu
zhush2@sysucc.org.cn
Zhu-qing Cheng
chengzq@sysucc.org.cn
Sheng Zhong
zhongsheng@sysucc.org.cn
Zhen-qiang He
hezhenq@sysucc.org.cn
Hao Duan
duanhao@sysucc.org.cn
Xia Wen
wenxia@sysucc.org.cn
Jian Wang
wangjian2@sysucc.org.cn

¹ Department of Neurosurgery, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Yuexiu District, Guangzhou 510060, People’s Republic of China
² State Key Laboratory of Oncology in South China, Guangzhou 510060, People’s Republic of China
³ Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People’s Republic of China
⁴ Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People’s Republic of China